DE03754425T1 - Anwendungen die in Bezug stehen mit durch Wasser stabilisierte medizinische Aerosolformulierungen - Google Patents
Anwendungen die in Bezug stehen mit durch Wasser stabilisierte medizinische Aerosolformulierungen Download PDFInfo
- Publication number
- DE03754425T1 DE03754425T1 DE03754425T DE03754425T DE03754425T1 DE 03754425 T1 DE03754425 T1 DE 03754425T1 DE 03754425 T DE03754425 T DE 03754425T DE 03754425 T DE03754425 T DE 03754425T DE 03754425 T1 DE03754425 T1 DE 03754425T1
- Authority
- DE
- Germany
- Prior art keywords
- formulation
- formulation according
- amino
- cyclopentyloxycarbonyl
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract 36
- 238000009472 formulation Methods 0.000 title claims abstract 33
- 239000000443 aerosol Substances 0.000 title claims abstract 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 9
- 239000003814 drug Substances 0.000 claims abstract 8
- -1 beclomethasone compound Chemical class 0.000 claims abstract 7
- 239000006184 cosolvent Substances 0.000 claims abstract 7
- 239000003380 propellant Substances 0.000 claims abstract 6
- 239000003381 stabilizer Substances 0.000 claims abstract 5
- 239000012453 solvate Substances 0.000 claims abstract 4
- 229940092705 beclomethasone Drugs 0.000 claims abstract 2
- 239000003246 corticosteroid Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 150000002617 leukotrienes Chemical class 0.000 claims 4
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 3
- 102000017910 Adrenergic receptor Human genes 0.000 claims 3
- 239000000048 adrenergic agonist Substances 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229960000265 cromoglicic acid Drugs 0.000 claims 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 2
- 229960000676 flunisolide Drugs 0.000 claims 2
- 229960002714 fluticasone Drugs 0.000 claims 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960001664 mometasone Drugs 0.000 claims 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000003287 optical effect Effects 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 2
- 229960002052 salbutamol Drugs 0.000 claims 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- IMJIXHAGGCVCPK-UHFFFAOYSA-N 3-[[5-(cyclopentyloxycarbonylamino)-3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]indole-1-carbonyl]amino]propanoic acid Chemical compound C=1N(C(=O)NCCC(O)=O)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C IMJIXHAGGCVCPK-UHFFFAOYSA-N 0.000 claims 1
- 229930003347 Atropine Natural products 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 1
- 239000004604 Blowing Agent Substances 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- QUQBHBRVKLEOEI-UBWIUKTRSA-N aldosterone hemiacetal Chemical compound C([C@@]12C)CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](OC2O)C[C@]32[C@@H](C(=O)CO)CC[C@H]31 QUQBHBRVKLEOEI-UBWIUKTRSA-N 0.000 claims 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 1
- 229960002576 amiloride Drugs 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 1
- 229960000396 atropine Drugs 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- JHIIPMNJGTTZQF-UHFFFAOYSA-N cyclopentyl n-[1-(diphenylcarbamoyl)-3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]indol-5-yl]carbamate Chemical compound C=1N(C(=O)N(C=2C=CC=CC=2)C=2C=CC=CC=2)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C JHIIPMNJGTTZQF-UHFFFAOYSA-N 0.000 claims 1
- GLLWUVJQYRZNHR-UHFFFAOYSA-N cyclopentyl n-[1-(hydroxycarbamoyl)-3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]indol-5-yl]carbamate Chemical compound C=1N(C(=O)NO)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C GLLWUVJQYRZNHR-UHFFFAOYSA-N 0.000 claims 1
- JCSUFOPUYUYANB-UHFFFAOYSA-N cyclopentyl n-[1-carbamoyl-3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]indol-5-yl]carbamate Chemical compound C=1N(C(N)=O)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C JCSUFOPUYUYANB-UHFFFAOYSA-N 0.000 claims 1
- YLDQXKDORFFTJP-UHFFFAOYSA-N cyclopentyl n-[3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-(pyrrolidine-1-carbonyl)indol-5-yl]carbamate Chemical compound C=1N(C(=O)N2CCCC2)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C YLDQXKDORFFTJP-UHFFFAOYSA-N 0.000 claims 1
- FPACABIHUTXCLO-UHFFFAOYSA-N cyclopentyl n-[3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-[methyl(phenyl)carbamoyl]indol-5-yl]carbamate Chemical compound C=1N(C(=O)N(C)C=2C=CC=CC=2)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C FPACABIHUTXCLO-UHFFFAOYSA-N 0.000 claims 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002011 fludrocortisone Drugs 0.000 claims 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960001361 ipratropium bromide Drugs 0.000 claims 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims 1
- 229940039009 isoproterenol Drugs 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229960005414 pirbuterol Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/234,825 US7074388B2 (en) | 1998-12-10 | 2002-09-03 | Water stabilized medicinal aerosol formulation |
| US234825 | 2002-09-03 | ||
| PCT/US2003/027245 WO2004022035A1 (en) | 2002-09-03 | 2003-09-03 | Water stabilized medicinal aerosol formulation related applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE03754425T1 true DE03754425T1 (de) | 2006-03-09 |
Family
ID=31977472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE03754425T Pending DE03754425T1 (de) | 2002-09-03 | 2003-09-03 | Anwendungen die in Bezug stehen mit durch Wasser stabilisierte medizinische Aerosolformulierungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7074388B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1569617A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006502160A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003272251A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2497171C (cg-RX-API-DMAC7.html) |
| DE (1) | DE03754425T1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2247959T1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05002337A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004022035A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60133203T3 (de) * | 2000-07-31 | 2012-02-23 | Nycomed Danmark Aps | Fentanyl Zusammensetzung für nasale Anwendung |
| EP1415647A1 (en) * | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
| ES2304616T3 (es) * | 2003-03-20 | 2008-10-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Formulacion para un inhalador con dosis medida utilizando hidro-fluoro-alcanos como propulsores. |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| US20060178394A1 (en) * | 2003-04-14 | 2006-08-10 | Staniforth John N | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
| AR041873A1 (es) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
| GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
| GB0604141D0 (en) * | 2006-03-01 | 2006-04-12 | Arrow Int Ltd | Nebulizer formulation |
| WO2009049159A1 (en) | 2007-10-10 | 2009-04-16 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
| WO2011034883A2 (en) * | 2009-09-15 | 2011-03-24 | Union Carbide Chemicals & Plastics Technology Llc (Formerly Union Carbide Chemicals & Plastics Technology Corporation) | Personal care compositions with ethylene acrylic acid copolymer aqueous dispersions |
| GB0918149D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| WO2012061195A2 (en) | 2010-11-04 | 2012-05-10 | Union Carbide Chemicals & Plastics Technology Llc | Skin care compositions |
| EP2717855A4 (en) | 2011-06-07 | 2014-11-12 | Parion Sciences Inc | Methods of Treatment |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| JP2017505348A (ja) | 2014-02-10 | 2017-02-16 | パタラ ファーマ リミテッド ライアビリティ カンパニー | 肺疾患治療のための肥満細胞安定剤 |
| PL3104853T3 (pl) | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| JP2019528320A (ja) | 2016-08-31 | 2019-10-10 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 |
| EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS |
| WO2019235616A1 (ja) | 2018-06-08 | 2019-12-12 | 東興薬品工業株式会社 | フルチカゾンフランカルボン酸エステル点鼻組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
| DE4446891A1 (de) * | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
| US6458338B1 (en) * | 1998-09-22 | 2002-10-01 | Aeropharm Technology Incorporated | Amino acid stabilized medicinal aerosol formulations |
| DE19847969A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähig flüssige Formulierung mit Formoterol |
| US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
| US6540983B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
| US6548049B1 (en) * | 2000-05-01 | 2003-04-15 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US6565833B1 (en) * | 2000-05-01 | 2003-05-20 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US6447750B1 (en) * | 2000-05-01 | 2002-09-10 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
-
2002
- 2002-09-03 US US10/234,825 patent/US7074388B2/en not_active Expired - Fee Related
-
2003
- 2003-09-03 MX MXPA05002337A patent/MXPA05002337A/es unknown
- 2003-09-03 ES ES03754425T patent/ES2247959T1/es active Pending
- 2003-09-03 WO PCT/US2003/027245 patent/WO2004022035A1/en not_active Ceased
- 2003-09-03 JP JP2004534386A patent/JP2006502160A/ja active Pending
- 2003-09-03 CA CA002497171A patent/CA2497171C/en not_active Expired - Fee Related
- 2003-09-03 DE DE03754425T patent/DE03754425T1/de active Pending
- 2003-09-03 AU AU2003272251A patent/AU2003272251A1/en not_active Abandoned
- 2003-09-03 EP EP03754425A patent/EP1569617A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05002337A (es) | 2005-12-05 |
| ES2247959T1 (es) | 2006-03-16 |
| JP2006502160A (ja) | 2006-01-19 |
| AU2003272251A1 (en) | 2004-03-29 |
| EP1569617A1 (en) | 2005-09-07 |
| CA2497171A1 (en) | 2004-03-18 |
| WO2004022035A1 (en) | 2004-03-18 |
| US20030091512A1 (en) | 2003-05-15 |
| CA2497171C (en) | 2009-04-28 |
| US7074388B2 (en) | 2006-07-11 |
| EP1569617A4 (en) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2010190B1 (en) | Pharmaceutical solution formulations for pressurised metered dose inhalers | |
| RU2327450C2 (ru) | Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды | |
| DE69232462T2 (de) | Formoterol und budesonide enthaltende zusammensetzung | |
| ES2247959T1 (es) | Formulacion medica en aerosol estabilizada en agua. | |
| AU759746B2 (en) | Pharmaceutical aerosol compositions | |
| EP1545634B1 (en) | Method of preparing dry powder inhalation compositions | |
| JP2006502160A5 (cg-RX-API-DMAC7.html) | ||
| HRP20140864T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergiäśke agoniste | |
| US20170027908A1 (en) | Pharmaceutical Composition | |
| SK92494A3 (en) | Pharmaceutical agent | |
| US8075873B2 (en) | Method of preparing dry powder inhalation compositions | |
| JP2024525567A5 (cg-RX-API-DMAC7.html) | ||
| JP2019528316A5 (cg-RX-API-DMAC7.html) | ||
| EP4585215A1 (en) | Pharmaceutical composition for inhalation for preventing or treating respiratory disease | |
| KR101475262B1 (ko) | 천식 치료에 사용되는 흡입용 복합 조성물 | |
| CN104955448A (zh) | 适用于吸入治疗的包含多组分结晶颗粒的药物组合物 | |
| TWI399202B (zh) | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 | |
| RU2012112454A (ru) | Фармацевтические аэрозольные препараты формотерола и беклометазона дипропионата | |
| EA007377B1 (ru) | Композиции для ингаляции | |
| US6623760B1 (en) | Method of preparing particles for agglomeration | |
| WO2017089404A1 (en) | Pharmaceutical composition | |
| US20050158248A1 (en) | Method of preparing dry powder inhalation compositions | |
| RU2422144C2 (ru) | Применение солей тиотропия для лечения тяжелых форм персистирующей астмы | |
| EP3166641B1 (en) | A process for the preparation of formulations for inhalation | |
| US20040241103A1 (en) | Pharmaceutical aerosol compositions |